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Avaliação da concentração de alfa 1-antitripsina e da presença dos alelos S e Z  
em uma população de indivíduos sintomáticos respiratórios crônicos
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Abstract
Objective: To determine the levels of alpha-1 antitrypsin (AAT) and the presence of S and Z alleles in patients with chronic respiratory symp-
toms. Methods: Patients with chronic cough and dyspnea were submitted to clinical evaluation, pulmonary function tests, high-resolution 
computed tomography, nephelometric determination of AAT and determination of S and Z alleles by polymerase chain reaction. Smoking 
and AAT levels were considered the dependent variables. Results: Of the 89 patients included in the study, 44 were female. The mean age was 
51.3 ± 18.2 years. The S and Z alleles were detected in 33.3% and 5.7%, respectively, and the gene frequency was 0.16 and 0.028, respec-
tively. Two patients were SZ heterozygotes (AAT levels ≤ 89 mg/dL). The patients were divided into groups based on AAT level: ≤ 89 mg/ dL 
(deficiency, no group); 90-140 mg/dL (intermediate, Group 1, n = 30); and ≥ 141 mg/dL (normal, Group 2, n = 57). The frequency of 
smokers was the same in both groups, although tobacco intake was greater in Group 2. The S allele was present in 13 and 14 patients in 
Groups 1 and 2, respectively, whereas the Z allele was present in 2 and 1 patient in the same groups. There was no difference in the results 
of pulmonary function tests or in the frequency of bronchiectasis or emphysema between the two groups. Spirometric values and AAT levels 
were similar in smokers and nonsmokers. Bronchiectasis was more common in nonsmokers, and emphysema was more common in smokers. 
Conclusions: Thirty patients presented AAT levels lower than the mean values found in patients with the MM or MS genotype, and this fact 
could not be explained by an increased frequency of S and Z alleles.
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Resumo
Objetivo: Determinar a concentração de alfa 1-antitripsina (AAT) e a prevalência dos alelos S e Z em indivíduos sintomáticos respiratórios 
crônicos. Métodos: Pacientes com tosse crônica e dispnéia foram submetidos à avaliação clínica, espirometria, tomografia computadorizada 
de tórax, dosagem de AAT por nefelometria e pesquisa das mutações S e Z por reação em cadeia da polimerase. Foram consideradas como 
variáveis dependentes a concentração de AAT e o tabagismo. Resultados: Dos 89 pacientes incluídos no estudo (44 mulheres; idade média, 
51,3 ± 18,2 anos), os alelos S e Z foram detectados em 33,3% e 5,7%, respectivamente, com freqüência gênica dos alelos S e Z de 0,16 e 0,028. 
Dois pacientes tinham genótipo SZ (AAT ≤ 89 mg/dL). Os pacientes foram divididos em grupos segundo a concentração de AAT: ≤ 89 mg/dL 
(deficiência, nenhum grupo); 90-140 mg/dL (faixa intermediária, Grupo 1, n = 30); e ≥ 141 mg/dL (normal, Grupo 2, n = 57). A freqüência 
de fumantes foi igual nos dois grupos, com carga tabágica maior no Grupo 2. O alelo S estava presente em 13 e 14 pacientes dos Grupos 1 e 
2, respectivamente, enquanto que o alelo Z estava presente em 2 e 1 paciente dos mesmos grupos. Não houve diferença nos testes de 
função pulmonar, nem na freqüência de bronquiectasias ou enfisema entre os dois grupos. Os valores espirométricos e as concentrações de 
AAT foram similares entre fumantes e não-fumantes. Bronquiectasias foram mais freqüentes entre os não fumantes, e enfisema foi mais 
freqüente entre os fumantes. Conclusões: Trinta pacientes apresentaram níveis de AAT abaixo da média esperada para os genótipos MM e 
MS, e este fato não pode ser explicado por uma freqüência maior dos alelos S e Z. 
Descritores: Alfa 1-antitripsina; Enfisema; Pneumopatias; Alelos.
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positivity for antineutrophil cytoplasmic antibodies 
with cytoplasmic pattern.(5)
The gene responsible for AAT synthesis is located 
on chromosome 14, and production occurs princi-
pally in hepatocytes, although other cells, such as 
mononuclear phagocytes and epithelial cells of the 
lung and intestine, can contribute. The highly pleo-
morphic nature of AAT indicates that the gene locus 
is also highly variable: approximately 100 different 
alleles have been identified to date. The vari-
ants are inherited codominantly and are classified 
according to the protease inhibitor (PI) system, 
which is based on the electrophoretic mobility of 
the different proteins on acrylamide gels. The most 
common phenotype, the MM (medium mobility) 
phenotype, is present in 94% to 96% of Caucasians 
and is associated with serum AAT levels within the 
150-350 mg/ dL range.(5)
Low serum and tissue levels of AAT occur as a 
result of the inheritance of two alleles (S and Z) that 
encode decreased levels of this protein.
The Z allele (PI*Z), when homozygous (PI*ZZ), 
results in serum AAT levels ranging from 15 to 
50 mg/dL. In this setting, panacinar pulmonary 
emphysema is the most common clinical manifesta-
tion, as well as being the leading cause of incapacity 
and death. The Z allele is the allele most commonly 
found in Caucasians coming from northern Europe, 
and accounts for 1-3% of all AAT alleles in such 
individuals.(2)
The S allele is more common than the Z allele, 
accounting for 2-4% of all AAT alleles in Caucasians 
from northern Europe and for 15% of all AAT 
alleles in individuals from the Iberian Peninsula, 
being especially prominent in those from northern 
Portugal and the region of Galicia, in Spain.(2,6)
The SZ genotype (PI*SZ) results in AAT levels 
ranging from 45 to 105 mg/dL, whereas the SS 
genotype (PI*SS) produces levels ranging from 100 to 
140 mg/dL.(7) Individuals who are SZ heterozygotes 
are three times more likely to develop COPD.(8)
The low frequency of S and Z alleles in the popu-
lation makes it difficult to obtain data on the gene 
frequency and the presence of AAT deficiency in 
the general population. In Brazil, given the level of 
laboratory sophistication required, there have been 
no studies involving epidemiological investigation 
in the general population.
Introduction
Neutrophils, which normally pass unimpeded 
through the pulmonary vascular system, adhere 
to the endothelium of capillaries and venules in 
response to activation by inflammatory stimuli. 
Neutrophil activation leads to the release of 
many substances, such as reactive oxygen species, 
cationic peptides, eicosanoids and proteo-
lytic enzymes, all of which have the function of 
destroying aggressor agents. The activity of those 
substances, however, needs to be controlled by 
antagonists in order to prevent tissue damage and 
organ dysfunction.
Serine proteases, a group of neutrophil proteolytic 
enzymes, have various functions, such as degrading 
elastic and collagen fibers, producing secretory cell 
metaplasia in the respiratory epithelium, affecting 
the ciliary beat, activating the complement system, 
increasing interleukin-8 synthesis and increasing 
tumor necrosis factor-alpha synthesis, as well as 
activating or inactivating various cytokines.(1)
Neutrophil elastase, which is the most important 
serine protease, is one of the few human enzymes 
capable of degrading elastic fibers, which are 
responsible for tissue elastic recoil, including that of 
the alveolar walls.(2)
Clinical and experimental lines of evidence have 
suggested that emphysema is caused by elastase-
induced destruction of elastic fibers of the lung 
interstitium. In 1963, two authors described five 
patients with alpha 1-antitrypsin (AAT) deficiency, 
AAT being the substance primarily responsible 
for neutrophil elastase inhibition; three of those 
patients had emphysema.(3) In 1965, one group 
of authors instilled papain (through the trachea) 
into the lung of rodents in an attempt to produce 
granulomas.(4) The authors discovered that papain 
caused emphysema.
Circulating at levels ranging from 120 to 
200 mg/ dL (measurements obtained by neph-
elometry), AAT is the principal inhibitor of serum 
protease. Significant reductions in serum and tissue 
AAT levels in human beings are associated with 
chronic obstructive pulmonary disease (COPD), in 
particular, as well as with pulmonary emphysema, 
with liver disease, which can lead to cirrhosis, 
necrotizing panniculitis and vasculites presenting 
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High-resolution computed tomography (using 
thin slices and a high-resolution algorithm) was 
performed with a GE-9800 scanner (General Electric 
Medical Systems, Milwaukee, WI, USA) or a SOMATON 
AR.T scanner (Siemens Medical Solutions, Munich, 
Germany). The department radiologist evaluated 
the scans for the presence of emphysema or bron-
chiectasis. No quantitative analysis of the lesions 
was performed, nor was the extent or severity of the 
lesions estimated.
The presence of S and Z alleles was determined 
by polymerase chain reaction, followed by enzymatic 
digestion of this amplified material with the restric-
tion enzymes XmnI (S allele) and TaqI (Z allele).(9) 
After the amplification of the DNA fragment and its 
enzymatic digestion, the samples were submitted to 
electrophoresis on a 16% polyacrylamide gel.
Nephelometric determination of serum AAT 
levels was performed using the Array 360 System 
(Beckman Instruments, Inc., Fullerton, CA, USA). 
The normal reference range for this test is from 
90 to 200 mg/dL.
The data obtained for each patient were 
analyzed in two ways: by using AAT levels as a 
dependent variable and by stratification based on 
the  presence / absence of smoking.
The project was approved by the Ethics in 
Research Committee of the institution, and all 
patients gave written informed consent prior to 
their enrollment in the study.
These facts have raised interest in determining 
the presence of S and Z alleles in the population 
of patients with chronic respiratory symptoms, 
without asthma, treated at the outpatient clinic 
of the Department of Pulmonology of a regional 
referral hospital.
The objective of the present study was to deter-
mine serum AAT levels, as well as to identify S and 
Z alleles, in a population of patients with chronic 
respiratory symptoms.
Methods
We selected patients with a clinical profile of 
productive cough and dyspnea treated at the outpa-
tient clinic of the Department of Pulmonology. 
Infectious causes, such as tuberculosis and fungal 
infections, were ruled out by testing sputum 
samples, and asthma was ruled out based on clinical 
history and spirometry results.
Clinical data (age, gender, race, history of 
smoking and tobacco intake) were collected, and 
patients were submitted to spirometry, high-
resolution computed tomography of the chest, 
determination of AAT levels and determination of 
S and Z alleles.
Pulmonary function tests were performed 
using a spirometer (model AM 4000 PC; Anamed, 
São Paulo, Brazil). Forced expiratory volume in 
one second (FEV1), forced vital capacity (FVC) 
and the ratio between the two (FEV1/FVC) were 
analyzed.
Table 1 - Clinical characteristics and spirometric parameters, as well as results of the determination of alpha-1 
antitrypsin levels and of the presence of S and Z alleles, in the patients evaluated.
Characteristica Group 1 Group 2 p
Patients, n 30 57
Age (years) 49.0 ± 17.9 52.1 ± 18.7 0.383
Smokers, n 17 33 0.9123
Tobacco intake (pack-years) 28.1 ± 20.4 45.4 ± 27.4 0.026
AAT levels (mg/dL) 121.6 ± 12.90 176.8 ± 35.80 0.0001
FVC, % of predicted (L) 60.5 ± 18.6 64.9 ± 21.5 0.340
FEV1, % of predicted (L) 41.8 ± 18.0 47.3 ± 21.9 0.393
VEF1/CVF 54.6 ± 14.1 58.0 ± 16.5 0.557
S allele, n/total 13/28 14/57 0.072
Z allele, n/total 2/28 1/57 0.272
aValues expressed as mean ± standard deviation, except when specified; Group 1: alpha-1 antitrypsin (AAT) levels of 90-140 mg/ dL 
(intermediate); Group 2: AAT levels ≥ 141 mg/dL (normal), FVC: forced vital capacity; and FEV1: forced expiratory volume in 
one second.
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The clinical characteristics, AAT levels, spirom-
etry findings and tomographic findings, as well as 
the results of the determination of S and Z alleles, 
for Groups 1 and 2 are listed in Table 1.
There was no difference in terms of the percentage 
of smokers (57% and 58% in Groups 1 and 2, 
respectively), although tobacco intake was signifi-
cantly different (p = 0.026), being greater in Group 2 
(45 pack-years) than in Group 1 (28 pack-years).
The S allele was present in 13 and 14 patients 
in Groups 1 and 2, respectively, compared with 
2 patients and 1 patient, respectively, for the Z 
allele. There was no significant difference between 
the two groups in terms of the presence of S or Z 
alleles (p = 0.072 and p = 0.272, respectively).
The comparison between Groups 1 and 2 in 
terms of tomographic findings revealed no differ-
ences in the frequency of bronchiectasis (p = 0.324) 
or emphysema (p = 0.938).
The analysis of AAT levels of the patients in 
Groups 1 and 2, taken together, in the presence or 
absence of the S allele (Table 2), revealed a signifi-
cant difference in the medians (p = 0.0089), with 
greater values in the group without the S allele.
A second analysis, considering all of the patients 
studied, compared smokers and nonsmokers in terms 
of AAT levels and spirometry results. No differences 
were found in any of the parameters (AAT levels, 
p = 0.585; FVC, p = 0.157; FEV1, p = 0.870; and 
FEV1/FVC, p = 0.134). However, smoking was found 
to be associated with presence of bronchiectasis 
and emphysema, in opposite ways: bronchiectasis 
was more common in nonsmokers (p = 0.008) 
and emphysema was more common in smokers 
(p = 0.032).
Discussion
Since this was a cross-sectional cohort study 
involving a population of patients with respiratory 
symptoms, the data obtained cannot be extrapo-
lated to the general population. The present study 
Statistical analysis of continuous data was 
performed using the parametric Student’s t-test or 
the nonparametric Wilcoxon test, when necessary. 
The correlations among categorical variables were 
studied using a parametric chi-square test or the 
nonparametric Fisher’s exact test, depending on the 
distribution of frequencies in a two-by-two table. 
The correlations among continuous variables were 
analyzed using Pearson and Spearman correlation 
tests. The SAS® (Statistical Analysis System, Cary, NC, 
USA) and the Minitab® (Minitab Inc., State College, 
PA, USA) statistical software were used for all tests. 
The level of statistical significance was set at 5%.
Results
A total of 89 patients (44 females and 45 males) 
were evaluated. The mean age was 51.3 ± 18.2 years. 
Of those, 87 were submitted to determination of S 
and Z alleles. The S allele was detected in 29 (33.3%) 
of the 87 patients evaluated, whereas the Z allele 
was detected in 5 (5.7%). The gene frequency of S 
and Z alleles was 0.160 and 0.028, respectively. The 
sample is in Hardy-Weinberg equilibrium (χ2 = 2.69; 
p = 0.61), which indicates that it is not subject to 
selection pressure and that the migration flow and 
the mutation rate are not significant to the point 
of affecting the interpretations of the analyses 
performed.
For the analysis of the results, the patients were 
divided into groups based on AAT levels, according 
to the cut-off values suggested in the guidelines for 
the diagnosis and management of individuals with 
AAT deficiency established by the American Thoracic 
Society (ATS) in collaboration with the European 
Respiratory Society (ERS)(5): ≤ 89 mg/ dL (deficiency); 
90-140 mg/dL (intermediate); and ≥ 141 mg/dL 
(normal).
Only 2 patients presented AAT levels ≤ 89 mg/ dL, 
a number that is insufficient for statistical analysis. 
Both of those patients were SZ heterozygotes, 
were heavy smokers (18 and 20 pack-years) and 
had COPD. One of the two patients had chronic 
respiratory insufficiency and used home oxygen 
therapy, whereas the other had a history of frequent 
exacerbations and presented bronchiectasis on the 
tomography scan. Among the 89 patients, AAT 
levels were 90-140 mg/dL in 30 and ≥ 141 mg/dL 
in 57. These were designated Group 1 and Group 2, 
respectively.
Table 2 - Alpha-1 antitrypsin levels in the presence or 
absence of the S allele.
Variable S allele Level, median 
(minimum-maximum)
p
AAT (mg/dL) Present 143 (105-181) 0.0089
Absent 166 (97-371)
AAT: alpha-1 antitrypsin.
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In addition, the two groups presented equal 
degrees of abnormality in the spirometry findings 
(p > 0.05). In Group 1, FVC (% of predicted) was 
60.5 ± 18.6 L, FEV1 (% of predicted) was 41.8 ± 18.0 L 
and the FEV1/FVC ratio was 54.6 ± 14.1, compared 
with 64.9 ± 21.5 L, 47.3 ± 21.9 L and 58.0 ± 16.5, 
respectively, in Group 2 (Table 1).
Based on the data presented above, we can 
conclude that, in the population studied, interme-
diate AAT levels were more common among patients 
who smoked less heavily. However, the intermediate 
AAT levels cannot be explained by a greater presence 
of S and Z alleles, since there was no statistically 
significant difference between the two groups in 
terms of the frequency of S and Z heterozygotes, 
which was 13/28 and 14/57 for S heterozygotes in 
Groups 1 and 2, respectively, compared with 2/28 
and 1/57, respectively, for Z heterozygotes (Table 1; 
p = 0.072 and p = 0.272, respectively). Nevertheless, 
it should be noted that the frequency of the S allele 
was greater in Group 1 than in Group 2, and the 
level of significance found in the comparison of the 
two groups (p = 0.072) seems to suggest a tendency 
that would eventually be confirmed if we had evalu-
ated a greater number of patients.
In a meta-analysis published in 2005,(8) the role 
of the S allele in the risk of COPD was investigated. 
The authors found that SZ heterozygotes were three 
times more likely to develop the disease. Regarding 
individuals with the MS genotype, cross-sectional 
and case-control studies have revealed a small but 
significant increase in the risk of COPD.
In addition, the median AAT levels were signifi-
cantly lower in patients with a single S allele 
(p = 0.0089) than in patients without the S or the 
Z allele (Table 2). In the present study, lower AAT 
levels, whether caused by the presence of a deficient 
allele or not, seemed to be associated with higher 
susceptibility to respiratory diseases. Since only S 
and Z alleles were investigated, we cannot rule out 
the possibility that patients with intermediate AAT 
levels have some known rare allele or even genetic 
alterations yet to be described, which could be 
detected only by gene sequencing.
There are nongenetic causes of AAT deficiency, 
such as liver diseases or other pathological conditions 
that lead to protein loss. However, those comorbidi-
was carried out in an institution that serves a region 
with approximately 4 million inhabitants, and, since 
this institution is a referral hospital for severe cases, 
the population treated represents the characteristic 
miscegenation of the Brazilian population, espe-
cially that of the state of São Paulo.
In the analysis of the results, we opted for 
using three serum AAT level ranges to define 
three groups: the first with AAT levels ≤ 89 mg/ dL 
(deficiency); the second with AAT levels of 
90-140 mg / dL (intermediate); and the third with 
AAT levels ≥ 141 mg/dL (normal). According to 
the ATS/ERS document,(5) even patients with 
intermediate AAT levels should be submitted to 
a qualitative test, such as phenotyping or geno-
typing, as was done in the present study, although 
AAT levels > 50 mg/dL are considered protective 
against the development of emphysema.
Decreased serum AAT levels should not have, 
a priori, any relationship with the smoking habit. 
In fact, since AAT is an acute phase protein, the 
expected effect of smoking on AAT levels would 
be that of an increase, due to the inflammatory 
process triggered by the substances present in 
tobacco smoke. There is evidence that, although 
not decreasing AAT levels in the blood and tissues, 
smoking can decrease AAT activity due to methio-
nine oxidation at the protein active site.(5) In the 
patients studied here, greater tobacco intake was 
associated with higher AAT levels (p = 0.026).
In our sample of 89 patients with chronic respi-
ratory symptoms, 30 (33.7%) were classified as 
having intermediate AAT levels, with mean serum 
levels of 121.6 ± 12.9 mg/dL, below the means 
predicted for individuals with the MM or MS alleles 
(149.1 ± 38.2 mg/dL and 150.0 ± 40.0 mg/dL, 
respectively).(10) In this group, designated Group 1, 
tobacco intake was significantly lower than that 
found in the group of patients with normal AAT 
levels. Considering the patient inclusion criteria 
adopted in the present study (chronic complaints of 
productive cough and dyspnea), we can infer, based 
on this finding, that patients with intermediate AAT 
levels had chronic respiratory symptoms, although 
they smoked less heavily than did the 57 individuals 
(64%) with normal AAT levels (Group 2, mean AAT 
levels of 176.8 ± 35.8 mg/dL).
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In summary, the S allele was detected in 33.3% 
of the 89 patients studied, whereas the Z allele was 
detected in 5.7%. The quantitative analysis of AAT 
levels revealed that 30 patients presented serum AAT 
levels lower than the mean values found in patients 
with the MM or MS genotype, who account for 
most of the population (94-96% of Caucasians).(5)
In Brazil, there are no data on the frequency of 
S and Z alleles or on the quantitative analysis of 
AAT levels in the general population. It can be said, 
however, that the AAT levels found, which were 
classified as intermediate, cannot be explained by 
an increased frequency of S and Z alleles in those 
patients. More comprehensive studies, preferably 
multicenter studies, are needed in order to deter-
mine the frequency of the principal alleles associated 
with AAT deficiency in Brazil.
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